Poseida Therapeutics (NASDAQ:PSTX) Downgraded by Cantor Fitzgerald to “Hold”

Cantor Fitzgerald lowered shares of Poseida Therapeutics (NASDAQ:PSTX) from a strong-buy rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

PSTX has been the subject of several other research reports. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. BTIG Research reaffirmed a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday. Finally, William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Stock Down 0.2 %

Poseida Therapeutics stock opened at $9.31 on Tuesday. Poseida Therapeutics has a one year low of $1.87 and a one year high of $9.42. The stock has a fifty day moving average of $3.25 and a 200 day moving average of $3.10. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The stock has a market cap of $907.35 million, a PE ratio of -14.78 and a beta of 0.54.

Insider Activity

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now owns 651,291 shares in the company, valued at approximately $6,037,467.57. This represents a 4.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Poseida Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in Poseida Therapeutics in the 3rd quarter worth approximately $37,000. Barclays PLC raised its position in shares of Poseida Therapeutics by 132.7% during the third quarter. Barclays PLC now owns 120,464 shares of the company’s stock valued at $345,000 after buying an additional 68,688 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of Poseida Therapeutics by 47.1% in the third quarter. XTX Topco Ltd now owns 182,888 shares of the company’s stock worth $523,000 after buying an additional 58,587 shares in the last quarter. State Street Corp boosted its position in shares of Poseida Therapeutics by 2.3% during the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after acquiring an additional 38,770 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new position in Poseida Therapeutics during the third quarter valued at $369,000. Institutional investors own 46.87% of the company’s stock.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.